Isotretinoin exposure and risk of inflammatory bowel disease

JAMA Dermatology

Volumn 150, Issue 12, 2014, Pages 1322-1326

  Rashtak, Shadi ^a   Khaleghi, Shahryar ^b   Pittelkow, Mark R ^c   Larson, Joseph J ^d   Lahr, Brian D ^d   Murray, Joseph A ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ISOTRETINOIN; MINOCYCLINE; TETRACYCLINE; DERMATOLOGICAL AGENT;

ACNE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; FAMILY HISTORY; FEMALE; FOLLICULITIS; HUMAN; ICD-9; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; RETROSPECTIVE STUDY; RISK FACTOR; ROSACEA; TREATMENT INDICATION; ULCERATIVE COLITIS; UNITED STATES; ACNE VULGARIS; ADOLESCENT; INFLAMMATORY BOWEL DISEASES; YOUNG ADULT;

ACNE VULGARIS; ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; ISOTRETINOIN; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84918583637     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.1540     Document Type: Article

References (27)

1. Martin P, Manley PN, DepewWT, Blakeman JM. Isotretinoin-Associated proctosigmoiditis. Gastroenterology. 1987;93(3):606-609
2. Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother. 2001;35(10):1214-1216
3. Passier JL, Srivastava N, van Puijenbroek EP. Isotretinoin-induced inflammatory bowel disease. Neth J Med. 2006;64(2):52-54
4. Spada C, Riccioni ME, Marchese M, Familiari P, Costamagna G. Isotretinoin-Associated pan-enteritis. J Clin Gastroenterol. 2008;42(8):923-925
5. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: A case-control study. Am J Gastroenterol. 2010;105(9):1986-1993
6. Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: A population-based case-control study. Am J Gastroenterol. 2009;104 (11):2774-2778
7. Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network. Isotretinoin use and the risk of inflammatory bowel disease: A population-based cohort study. J Invest Dermatol. 2013;133(4):907-912
8. Rolanda C, Macedo G. Isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2007;102(6):1330
9. Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101(7): 1569-1573
10. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12): 1424-1429
11. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J AmAcad Dermatol. 2002;46(4):505-509
12. Prokop LD. Isotretinoin: Possible component cause of inflammatory bowel disease. Am J Gastroenterol. 1999;94(9):2568
13. Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis. 1993;8(3):117-119
14. Borghi A, Mantovani L, Minghetti S, Virgili A, Bettoli V. Acute acne flare following isotretinoin administration: Potential protective role of low starting dose. Dermatology. 2009;218(2):178-180
15. Guslandi M. Isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2007;102(7): 1546-1547
16. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610-2616
17. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: A nested case-control study and meta-Analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216-220
18. Racine A, Cuerq A, Bijon A, et al. Isotretinoin and risk of inflammatory bowel disease: A French nationwide study. Am J Gastroenterol. 2014;109(4): 563-569
19. Etminan M. Study website. http://www .broadmedical.org/asset/1406-finalprogressreport -etminan2.pdf. Accessed July 28, 2014
20. Muci dA D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317(5835):256-260
21. Coombs JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204(8):1757-1764
22. Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003;15(8): 1017-1025
23. Zhu YF, Hu JZ, Zhao PN, Liu LX, Li Y. All-transretinoic acid regulates Th1/Th2 balance in CD4+ T cells when GATA-3 is deficient. Biomed Environ Sci. 2013;26(9):774-777
24. Walsh D, McCarthy J, O'Driscoll C, Melgar S. Pattern recognition receptors: Molecular orchestrators of inflammation in inflammatory bowel disease. Cytokine Growth Factor Rev. 2013; 24(2):91-104
25. Szebeni B, Veres G, Dezsofi A, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol. 2008;151(1):34-41
26. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66(11):5224-5231
27. Dispenza MC,Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012; 132(9):2198-2205.